{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:24:12Z","timestamp":1793064252829,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.euf.2024.11.003","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T07:25:55Z","timestamp":1732173955000},"page":"374-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies"],"prefix":"10.1016","volume":"11","author":[{"given":"Akihiro","family":"Matsukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Kardoust Parizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mancon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Klemm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cadenar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.11.003_b0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.11.003_b0010","first-page":"28","article-title":"Can we lower the rates of cystectomy complications by modifying risk factors? A review of the literature","volume":"75","author":"Hladun","year":"2022","journal-title":"Cent European J Urol"},{"key":"10.1016\/j.euf.2024.11.003_b0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","article-title":"A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer","volume":"25","author":"Yang","year":"2016","journal-title":"Surg Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12094-023-03264-9","article-title":"Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival","volume":"26","author":"Tang","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b0025","doi-asserted-by":"crossref","first-page":"272.e1","DOI":"10.1016\/j.urolonc.2021.12.015","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder","volume":"40","author":"Softness","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12957-023-03161-z","article-title":"Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis","volume":"21","author":"Su","year":"2023","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2023.1276746","article-title":"Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis","volume":"10","author":"Al-Qudimat","year":"2023","journal-title":"Front Surg"},{"key":"10.1016\/j.euf.2024.11.003_b0040","article-title":"Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: a meta-analysis. Front","volume":"10","author":"Ding","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b0045","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s00345-018-2384-6","article-title":"Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis","volume":"36","author":"Garc\u00eda-Perdomo","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2024.11.003_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.euf.2024.11.003_b0055","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2024.11.003_b0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.euf.2024.11.003_b0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0145445516673998","article-title":"Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data","volume":"41","author":"Drevon","year":"2017","journal-title":"Behav Modif"},{"key":"10.1016\/j.euf.2024.11.003_b0070","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euf.2024.11.003_b0075","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2024.11.003_b0080","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2024.11.003_b0085","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euf.2024.11.003_b0090","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.178","article-title":"Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives","volume":"3","author":"Lin","year":"2020","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.euf.2024.11.003_b0095","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","article-title":"Meta-analysis of proportions using generalized linear mixed models","volume":"31","author":"Lin","year":"2020","journal-title":"Epidemiology"},{"key":"10.1016\/j.euf.2024.11.003_b0100","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b0105","first-page":"11686","article-title":"Propensity score matched survival analysis of octogenarians with muscle-invasive bladder cancer: chemoradiation compared to radical cystectomy","volume":"30","author":"Avudaiappan","year":"2023","journal-title":"Can J Urol"},{"key":"10.1016\/j.euf.2024.11.003_b0110","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7306198","article-title":"Comparing long-term survival outcomes for muscle-invasive bladder cancer patients who underwent with radical cystectomy and bladder-sparing trimodality therapy: a multicentre cohort analysis","volume":"2022","author":"Qiu","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b0115","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.21037\/tau-20-1351","article-title":"Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study)","volume":"10","author":"Iwamura","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euf.2024.11.003_b0120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000477912","article-title":"The efficacy of trimodal chemoradiotherapy with cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer","volume":"99","author":"Nagao","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.euf.2024.11.003_b0125","doi-asserted-by":"crossref","first-page":"68996","DOI":"10.18632\/oncotarget.16576","article-title":"Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2024.11.003_b0130","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE\u2014a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2024.11.003_b0135","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-023-37477-3","article-title":"Leveraging deep survival models to predict quality of care risk in diverse hospital readmissions","volume":"13","author":"Tran","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.euf.2024.11.003_b0140","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1093\/cid\/ciaa169","article-title":"Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of Gram-negative bloodstream infections","volume":"71","author":"Amoah","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.euf.2024.11.003_b0145","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.euf.2024.11.003_b0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euf.2022.12.012","article-title":"Efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: the MK-3475-992\/KEYNOTE-992 trial","volume":"9","author":"Tissot","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.11.003_b0155","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1200\/JCO.2021.39.6_suppl.428","article-title":"INTACT (S\/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: safety update on first 73 patients","volume":"39","author":"Singh","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b0160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.11.003_b0165","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.11.003_b0170","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.euf.2023.04.009","article-title":"For which patients should bladder preservation be considered after a complete response to neoadjuvant chemotherapy","volume":"9","author":"Laukhtina","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.11.003_b0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JU.0000000000001696","article-title":"Complications and outcomes of salvage cystectomy after trimodality therapy","volume":"206","author":"Pieretti","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.11.003_b0180","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/JU.0000000000001380","article-title":"Rates and patterns of recurrences and survival outcomes after robot-assisted radical cystectomy: results from the international robotic cystectomy consortium","volume":"205","author":"Elsayed","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2024.11.003_b0185","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.kjms.2014.03.011","article-title":"Local and systemic recurrence patterns of urothelial cancer after radical cystectomy","volume":"30","author":"Ozbir","year":"2014","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.euf.2024.11.003_b0190","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.euf.2023.05.002","article-title":"Complications after radical cystectomy: a systematic review and meta-analysis of randomized controlled trials with a meta-regression analysis","volume":"9","author":"Katsimperis","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2024.11.003_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110038","article-title":"Quality of life after definitive treatment for bladder cancer: a systematic review and meta-analysis","volume":"190","author":"Francolini","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b0200","doi-asserted-by":"crossref","first-page":"273.e1","DOI":"10.1016\/j.urolonc.2022.01.007","article-title":"Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer","volume":"40","author":"Golla","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2024.11.003_b9000","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/jjco\/hyr064","article-title":"Primary cT2 bladder cancer: a good candidate for radiotherapy combined with cisplatin for bladder preservation","volume":"41","author":"Hara","year":"2011","journal-title":"Jpn J Clin Oncol."}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692400244X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692400244X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:15:47Z","timestamp":1760073347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545692400244X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S240545692400244X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.11.003","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}